Nuvation Bio Inc.
NUVBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. Valued at $1.71B, NUVB is a small-cap name in its sector. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Market Cap
$1.71B
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
-81.67
EPS (TTM)
$-0.43
EPS (Fwd)
$-0.06
ROE
-39.5%
ROA
-17.0%
Cash
$533.7M
Total Debt
$217.0M
Free CF
-$100.0M
52W Change
100.0%
Annual Financials
Cash vs Debt
Nuvation Bio Inc. holds $533.7M in cash against $217.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$100.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -39.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.52 means NUVB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuvation Bio Inc.'s trajectory.